data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Inventiva
(NASDAQ:IVA)
9.05
-0.13[-1.42%]
At close: May 27
11.38
2.33[25.75%]
After Hours: 4:00AM EDT
Day High/Low9 - 9.2
52 Week High/Low8 - 16.93
Open / Close9.2 / 9.05
Float / Outstanding- / 40.9M
Vol / Avg.5.4K / 5.9K
Mkt Cap369.9M
P/E-
50d Avg. Price10.2
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float-

Inventiva (NASDAQ:IVA), Quotes and News Summary

Inventiva (NASDAQ: IVA)

Day High/Low9 - 9.2
52 Week High/Low8 - 16.93
Open / Close9.2 / 9.05
Float / Outstanding- / 40.9M
Vol / Avg.5.4K / 5.9K
Mkt Cap369.9M
P/E-
50d Avg. Price10.2
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float-
Benzinga - May 16, 2022, 12:24PM
Benzinga - Mar 8, 2022, 6:22AM
Benzinga - Mar 7, 2022, 4:33PM
Benzinga - Jan 31, 2022, 4:01PM
Benzinga - Dec 16, 2021, 4:00PM
Benzinga - Dec 7, 2021, 7:15AM
Benzinga - Dec 6, 2021, 4:01PM
Benzinga - Nov 22, 2021, 11:15AM
Benzinga - Oct 28, 2021, 7:15AM
Benzinga - Oct 27, 2021, 4:28PM
Benzinga - Oct 20, 2021, 5:08PM
Benzinga - Sep 22, 2021, 7:01AM
Benzinga - Sep 22, 2021, 6:25AM
Benzinga - Sep 21, 2021, 4:00PM
Benzinga - Sep 20, 2021, 4:13PM
Benzinga - Sep 16, 2021, 4:01PM
Benzinga - Sep 8, 2021, 4:02PM
Benzinga - Aug 2, 2021, 5:00PM
Benzinga - Jul 28, 2021, 4:01PM
load more
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.
Read More

Earnings

see more
H1 2022Est.ActualSurprise
EPS
(EXPECTED)2022-07-27
REV
FY 2021Est.ActualSurprise
EPS-1.500
REV4.963M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Inventiva Questions & Answers

Q
How do I buy Inventiva (IVA) stock?
A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Inventiva's (IVA) competitors?
Q
What is the target price for Inventiva (IVA) stock?
A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Monday, November 22, 2021. The analyst firm set a price target for 42.00 expecting IVA to rise to within 12 months (a possible 364.09% upside). 2 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Inventiva (IVA)?
A

The stock price for Inventiva (NASDAQ: IVA) is $9.05 last updated May 27, 2022, 7:59 PM UTC.

Q
Does Inventiva (IVA) pay a dividend?
A

There are no upcoming dividends for Inventiva.

Q
When is Inventiva (NASDAQ:IVA) reporting earnings?
A

Inventiva’s H1 earnings are confirmed for Wednesday, July 27, 2022.

Q
Is Inventiva (IVA) going to split?
A

There is no upcoming split for Inventiva.

Q
What sector and industry does Inventiva (IVA) operate in?
A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.